Hans Pharmaceuticals (03692.HK): HS-10542 Capsules have obtained the drug clinical trial approval notice issued by the National Medical Products Administration.

Zhitan Finance APP News, Hansen Pharmaceuticals (03692.HK) announced that the group's independently developed new drug HS-10542 capsules have received the drug clinical trial approval notice issued by the China National Medical Products Administration (NMPA), and are intended to be used in clinical trials for paroxysmal nocturnal hemoglobinuria and immunoglobulin A nephropathy.